文献速递心力衰竭与心肌病

利用临床表观遗传学应对射血分数保留的心力衰竭:呼吁个体化治疗

Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
PubMed 文献 · Eur Heart J · 2021-01-01

该综述指出,射血分数保留的心力衰竭(HFpEF)占新发心衰诊断的65%,在女性中更常见,预后差且医疗成本高,目前尚无有效治疗。文章提出表观遗传修饰(DNA、组蛋白和非编码RNA改变)是环境调控基因表达的分子框架,与氧化应激、炎症、代谢异常和不良左室重构相关,高通量测序、计算表观遗传学和机器学习已能识别可靠的表观遗传生物标志物,且已有FDA批准的「表观药物」可预防左室重构和HFpEF相关的转录改变,呼吁将临床表观遗传学用于HFpEF的个体化管理。

要点

  • HFpEF占新发心衰诊断的65%,女性更常见,预后差且医疗成本高,目前尚无有效治疗。
  • 表观遗传修饰通过染色质重塑影响氧化应激、炎症、代谢异常和不良左室重构等HFpEF相关过程。
  • 表观遗传生物标志物可反映环境和生活方式影响且可逆,FDA批准的表观药物有望预防左室重构和HFpEF。

核心结论

  • 临床表观遗传学可作为HFpEF个体化管理的新工具,表观遗传生物标志物和表观药物在诊断与治疗方面具有前景。

研究设计与样本

  • 综述,讨论临床表观遗传学在HFpEF个体化管理中的应用。

主要发现

  • HFpEF占新发心衰诊断的65%,在女性中更常见,与不良预后和不可持续的医疗成本相关。
  • 表观遗传信号通过染色质重塑影响氧化应激、炎症、代谢异常和不良左室重构等HFpEF易感条件。
  • 高通量测序、计算表观遗传学和机器学习已能在心血管患者中识别可靠的表观遗传生物标志物。
  • 表观遗传生物标志物反映环境线索和生活方式改变的贡献,其可逆性为监测疾病状态提供机会。
  • 针对染色质和非编码RNA生物学已开发出多种FDA批准的表观药物(染色质修饰剂、模拟物、anti-miRs),能够预防左室重构和HFpEF相关的转录改变。

临床怎么用

  • 可考虑利用表观遗传生物标志物监测HFpEF疾病状态并指导个体化治疗。
  • 表观药物(染色质修饰剂、模拟物、anti-miRs)有望预防左室重构和HFpEF相关的转录改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Described as the 'single largest unmet need in cardiovascular medicine', heart failure with preserved ejection fraction (HFpEF) remains an untreatable disease currently representing 65% of new heart failure diagnoses. HFpEF is more frequent among women and associates with a poor prognosis and unsustainable healthcare costs. Moreover, the variability in HFpEF phenotypes amplifies complexity and difficulties in the approach. In this perspective, unveiling novel molecular targets is imperative. Epigenetic modifications-defined as changes of DNA, histones, and non-coding RNAs (ncRNAs)-represent a molecular framework through which the environment modulates gene expression. Epigenetic signals acquired over the lifetime lead to chromatin remodelling and affect transcriptional programmes underlying oxidative stress, inflammation, dysmetabolism, and maladaptive left ventricular remodelling, all conditions predisposing to HFpEF. The strong involvement of epigenetic signalling in this setting makes the epigenetic information relevant for diagnostic and therapeutic purposes in patients with HFpEF. The recent advances in high-throughput sequencing, computational epigenetics, and machine learning have enabled the identification of reliable epigenetic biomarkers in cardiovascular patients. Contrary to genetic tools, epigenetic biomarkers mirror the contribution of environmental cues and lifestyle changes and their reversible nature offers a promising opportunity to monitor disease states. The growing understanding of chromatin and ncRNAs biology has led to the development of several Food and Drug Administration approved 'epidrugs' (chromatin modifiers, mimics, anti-miRs) able to prevent transcriptional alterations underpinning left ventricular remodelling and HFpEF. In the present review, we discuss the importance of clinical epigenetics as a new tool to be employed for a personalized management of HFpEF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hamdani N, Costantino S, Mügge A, et al. Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. Eur Heart J. 2021. PMID: 33948637. doi:10.1093/eurheartj/ehab197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。